anti-CD138 × anti-CD3 bispecific engager-armed T cells

anti-CD138 × anti-CD3 bispecific engager-armed T cells (CD138-BATs) are an adoptive cellular immunotherapy being investigated for the treatment of multiple myeloma. The therapy involves coating (arming) T cells with a bispecific protein engager (BiPE) that possesses dual specificity for the CD3 epsilon chain on T cells and CD138 (syndecan-1) on tumor cells. CD138 is a heparan sulfate proteoglycan highly expressed on malignant plasma cells in multiple myeloma, making it an ideal target for redirection. By arming the T cells ex vivo, the BiPE acts as a bridge, redirecting the T cells' natural cytotoxic capacity toward CD138-positive cancer cells without the need for genetic modification, such as that required for CAR-T cells. This approach aims to combine the immediate availability and specificity of bispecific antibodies with the sustained effector function and trafficking capabilities of live T cells, potentially offering a safer and more persistent alternative to soluble bispecific T-cell engagers (BiTEs).

Other names

CD138-targeted bispecific protein engager-armed T cellsCD-138-targeted bispecific protein engager-armed T cellsCD 138-targeted bispecific protein engager-armed T cellsCD138-BiPE-armed T cellsCD-138-BiPE-armed T cellsCD 138-BiPE-armed T cellsCD138-targeted BATsCD-138-targeted BATsCD 138-targeted BATs